Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.

about

Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice

P2860

Q58797496-A88E281D-0709-4FBE-AA93-67E62C05C61F

P2860

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.

Item

http://www.wikidata.org/entity/Q38705330

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Co-clinical trials demonstrate ...... lung squamous cell carcinoma.

@en

type

Item

label

Co-clinical trials demonstrate ...... lung squamous cell carcinoma.

@en

prefLabel

Co-clinical trials demonstrate ...... lung squamous cell carcinoma.

@en

P1476

Co-clinical trials demonstrate ...... n lung squamous cell carcinoma

@en

P2093

C Y Lee

http://www.w3.org/2001/XMLSchema#string

D J Kim

http://www.w3.org/2001/XMLSchema#string

E Y Kim

http://www.w3.org/2001/XMLSchema#string

H A Youn

http://www.w3.org/2001/XMLSchema#string

H J Park

http://www.w3.org/2001/XMLSchema#string

H Kim

http://www.w3.org/2001/XMLSchema#string

H N Kang

http://www.w3.org/2001/XMLSchema#string

H R Kim

http://www.w3.org/2001/XMLSchema#string

J G Lee

http://www.w3.org/2001/XMLSchema#string

J Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

The Evolution of Therapies in Non-Small Cell Lung Cancer

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity

The NCI60 human tumour cell line anticancer drug screen

Epidemiology of lung cancer and approaches for its prediction: a systematic review and analysis.

P304

1250-1259

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDX098

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28460066

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.

about

P2860

P2860

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921